维利西呱治疗慢性射血分数降低的心力衰竭的研究进展  

Research progress of vericiguat in the treatment of chronic heart failure with reduced ejection fraction

作　　者：李卓东 杨倩[1] 姚文静[1] 容春莉[1] LI Zhuodong;YANG Qian;YAO Wenjing;RONG Chunli(Department of Cardiology,Hebei General Hospital,Shijiazhuang,050000,China)

机构地区：[1]河北省人民医院心内科,石家庄050000

出　　处：《临床心血管病杂志》2023年第3期182-187,共6页Journal of Clinical Cardiology

摘　　要：可溶性鸟苷酸环化酶(sGC)激动剂是一种新型的治疗心力衰竭的药物。它通过刺激sGC发挥作用,对心肌和血管功能有益处。维利西呱是首个被批准用于治疗成人有症状的慢性射血分数降低的心力衰竭(HFrEF)的口服sGC激动剂。该药耐受性良好,值得在临床中应用推广。现就其治疗慢性HFrEF的药理作用、疗效及耐受性等作一综述,以期为临床合理用药提供帮助。Soluble guanylate cyclase(sGC) stimulators is a new drug in the treatment of heart failure. It works by stimulating sGC and is good for myocardial and vascular function. Vericiguat is the first oral sGC stimulator to be approved for the treatment of symptomatic chronic HFrEF in adults. The drug is well tolerated and is worth popularizing in clinical practice. This article reviews its pharmacological effects, efficacy and tolerance in the treatment of chronic HFrEF, in order to provide help for clinical rational drug use.

关 键 词：可溶性鸟苷酸环化酶激动剂 维利西呱 心力衰竭 射血分数降低 

分 类 号：R541.6[医药卫生—心血管疾病]